Medsir

Medsir company information, Employees & Contact Information

Explore related pages

Related company profiles:

MEDSIR is an international private company that was founded by scientific experts in oncology back in 2012. We are dedicated to the design and management of strategic clinical trials in oncology, from the initial study conception to the final publication of results. We act as the link between our international network of brilliant oncology investigators and the parties (Pharma Companies, Biotechs, Public Institutions, etc.) interested in providing the funding for their clinical research ideas. We help transform the most promising concepts from all around the world into strategic clinical trials that promote patient benefit, scientific advancement, and efficient drug development. Today we support more than 200 ideas involving the most innovative drugs on the market and in development, optimizing every step of investigator-initiated research. Our international team of high-level clinicians and research experts are passionate about collaborating with top medical oncologists and pharmaceutical companies in order to help them develop the best treatments for patients as quickly as possible. Want to know more about us? Feel free to visit our website: www.medsir.org Work with us & Bring your idea to life! #WeAreMEDSIR At MEDSIR we have carried out the adaptation to the General Data Protection Regulation. Before following our profile, please consult our Privacy Policy available at https://medsir.org/privacy-policy/

Company Details

Employees
128
Founded
-
Address
Avinguda Diagonal, 211, 27,united States
Industry
Research Services
NAICS
Scientific Research and Development Services
Research and Development in the Physical, Engineering, and Life Sciences
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
HQ
Barcelona, Catalonia
Looking for a particular Medsir employee's phone or email?

Medsir Questions

News

Spanish oncology research group MEDSIR infuses AI into breast cancer trials - Fierce Biotech

Spanish oncology research group MEDSIR infuses AI into breast cancer trials Fierce Biotech

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer - Business Wire

Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer Business Wire

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers - PR Newswire

MEDSIR presents new studies at ESMO that advance treatment of patients with poor prognosis cancers PR Newswire

3rd MEDSIR Academy: Empowering research and advancing patient outcomes - Oncodaily

3rd MEDSIR Academy: Empowering research and advancing patient outcomes Oncodaily

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer - PR Newswire

Experts ensure that early detection and proper prevention are key to tackling the future challenges of cancer PR Newswire

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial - The Lancet

3-year invasive disease-free survival with chemotherapy de-escalation using an 18F-FDG-PET-based, pathological complete response-adapted strategy in HER2-positive early breast cancer (PHERGain): a randomised, open-label, phase 2 trial The Lancet

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL - PR Newswire UK

REVEAL GENOMICS® ANNOUNCES POSITIVE TOP-LINE RESULTS FOR HER2DX® IN MEDSIR'S PHERGAIN TRIAL PR Newswire UK

HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options - PR Newswire

HER3-DXd shows promising results in the phase II TUXEDO-3 study for patients with limited therapeutic options PR Newswire

MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer - PR Newswire

MEDSIR's PHERGain Trial Shows Potential for Chemotherapy-free Treatment of HER2-positive Early Breast Cancer PR Newswire

MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer - PR Newswire

MEDSIR's PRIMED Study Shows Promising Results for Preventing Sacituzumab Govitecan related Side Effects in the Treatment of HER2-negative Advanced Breast Cancer PR Newswire

The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression - PR Newswire

The results of the EMPRESS study show the activity of giredestrant in reducing tumor proliferation in ER+/HER2- breast cancer at early stages without the need for ovarian function suppression PR Newswire

MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients - PR Newswire

MEDSIR Study Finds No Progression-Free Survival Benefit with Palbociclib Maintenance After First-Line Regimen in HR+/HER2- Advanced Breast Cancer Patients PR Newswire

The most innovative research arrives in Latin America from the hand of MEDSIR - PR Newswire

The most innovative research arrives in Latin America from the hand of MEDSIR PR Newswire

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer - PR Newswire

The Lancet publishes positive results from the PHERGain study in patients with localized HER2-positive breast cancer PR Newswire

Jyoti Mundra, PhD, appointed as new Chief Business Officer at MEDSIR - PR Newswire

Jyoti Mundra, PhD, appointed as new Chief Business Officer at MEDSIR PR Newswire

Top Medsir Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant